Myfembree, a fixed-dose combination of relugolix, estradiol, and norethindrone acetate, is approved for premenopausal women with heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with …
Mineralocorticoid receptor antagonists, spironolactone, eplerenone, and finerenone, are cornerstone therapies in cardiovascular and renal diseases. While their efficacy is established, a systematic, head-to-head comparison of their post-marketing safety profiles based …
Elagolix and Myfembree are gonadotropin-releasing hormone (GnRH)-pathway therapies used for endometriosis, but their post-marketing safety reporting patterns remain incompletely characterized. Because spontaneous reporting databases are susceptible to reporting bias and …
Spironolactone, eplerenone, and finerenone are three commonly used mineralocorticoid receptor antagonists (MRAs) with cardioprotective and renoprotective effects. However, comparative real-world safety evaluations remain limited. This study aimed to assess and …
Systemic isotretinoin remains the most effective therapy for severe acne and is increasingly prescribed off-label for milder disease and other sebaceous disorders such as rosacea, seborrhea, folliculitis decalvans, and hidradenitis …
Spironolactone, a potassium-sparing diuretic, is commonly prescribed for conditions such as heart failure, hypertension, and hyperaldosteronism. This study aims to explore and analyze the safety profile of spironolactone by examining …
Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data Nature
Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. …
Real-World Study on Adverse Drug Reactions of Pembrolizumab in Endometrial Cancer Treatment: Insights from the FAERS Database Frontiers
Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.